$XBI $135.43 -3.22% 📉
Want to access our searchable database of catalysts and more? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$APLS (+0.29%) Apellis will not pursue additional development of APL-9 for severe COVID-19 source
Pipeline Updates
$GLPG (+3.11%) Report primary endpoint results in MANTRA and MANTRA-Ray safety studies source
$KRON (+3.02%) Positive End-of-Phase 2 meeting with FDA for Entospletinib source
$GLYC (-2.94%) First patient dosed in China phase 1 APL-106 trial source
$LUMO (-5.82%) Published data supporting use of predictive enrichment markers for LUM-201 in Journal of the Endocrine Society source
$OCUL (-1.37%) Acceptance of sNDA for Dextenza for ocular itching associated with allergic conjunctivitis source
$ALXO (-3.15%) ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics source
Financial Updates
$ENDP (+0.58%) Commence refinancing of existing term loan source
$SLDB (-10.72%) Inducement Grant to New Chief Legal Officer source
$AMGN (-0.91%) Amgen to acquire Five Prime Therapeutics source
$GILD (+0.77%) Gilead completes acquisition of MYR GmbH source
$RDHL (-3.35%) Closing of public offering of 4,375,000 ADSs source